Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Aclarubicin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 known ✓ | P23219 | 4/20 | 0.99 |
| ▸ | HTR2B known ✓ | P41595 | 2/20 | 0.99 |
| ▸ | HSP90AA1 known ✓ | P07900 | 4/20 | 0.43 |
| ▸ | HDAC6 known ✓ | Q9UBN7 | 1/20 | 0.37 |
| ▸ | TOP2A known ✓ | P11388 | 3/20 | 0.37 |
| ▸ | HSP90AB1 known ✓ | P08238 | 2/20 | 0.37 |
| ▸ | CHRM1 known ✓ | P11229 | 2/20 | 0.36 |
| ▸ | ADRA1A known ✓ | P35348 | 2/20 | 0.36 |
| ▸ | ESR1 known ✓ | P03372 | 1/20 | 0.36 |
| ▸ | NR3C1 known ✓ | P04150 | 1/20 | 0.36 |
| ▸ | ERBB2 known ✓ | P04626 | 1/20 | 0.36 |
| ▸ | LCK known ✓ | P06239 | 1/20 | 0.36 |
| ▸ | ADRA2A known ✓ | P08913 | 1/20 | 0.36 |
| ▸ | TOP1 known ✓ | P11387 | 1/20 | 0.36 |
| ▸ | HTR2A known ✓ | P28223 | 1/20 | 0.36 |
| ▸ | PTGS2 known ✓ | P35354 | 1/20 | 0.36 |
| ▸ | TOP2B known ✓ | Q02880 | 1/20 | 0.36 |
| ▸ | KCNH2 known ✓ | Q12809 | 1/20 | 0.36 |
| ▸ | CHRM2 known ✓ | P08172 | 1/20 | 0.36 |
| ▸ | ACHE known ✓ | P22303 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Aclarubicin SCHEMBL30077507 | 1.00 | PTGS1 (0.99) | PTGS1MMP2HTR2BMEN1KMT2A | |
| Aclarubicin SCHEMBL16767437 | 1.00 | PTGS1 (0.99) | PTGS1MMP2HTR2BMEN1KMT2A | |
| Aclarubicin SCHEMBL31238190 | 1.00 | PTGS1 (0.99) | PTGS1MMP2HTR2BMEN1KMT2A | |
| Aclarubicin SCHEMBL6255351 | 0.99 | PTGS1 (1.00) | PTGS1MMP2HTR2BMEN1KMT2A | |
| Aclarubicin SCHEMBL10201119 | 0.99 | PTGS1 (1.00) | PTGS1MMP2HTR2BMEN1KMT2A | |
| Aclarubicin SCHEMBL17035568 | 0.99 | PTGS1 (1.00) | PTGS1MMP2HTR2BMEN1KMT2A | |
| Aclarubicin SCHEMBL31277372 | 0.99 | PTGS1 (1.00) | PTGS1MMP2HTR2BMEN1KMT2A | |
| Aclarubicin SCHEMBL10061856 | 0.99 | PTGS1 (1.00) | PTGS1MMP2HTR2BMEN1KMT2A | |
| Aclarubicin SCHEMBL10079204 | 0.99 | PTGS1 (1.00) | PTGS1MMP2HTR2BMEN1KMT2A | |
| Aclarubicin SCHEMBL31238004 | 0.99 | PTGS1 (1.00) | PTGS1MMP2HTR2BMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2100 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119679758-A | Preparation method and application of graphene oxide microcapsule carrying hydrophilic drug | 东北大学 | 2025-03-25 | — | — | CN | claimed |
| WO-2022144780-A1 | SULFONAMIDE DERIVATIVES, COMPOSITIONS COMPRISING SAME AND USES THEREOF IN THE TREATMENT OF CANCERS | NATIONAL CANCER CENTER (JP) | 2022-07-07 | — | — | WO | claimed |
| CN-109806252-B | Ternary composite nano system and preparation method and application thereof | 中国药科大学 | 2021-08-10 | — | — | CN | claimed |
| CN-110354099-B | Proton-triggered nano-drug system with hydrophilic-hydrophobic-size double conversion characteristics and preparation method and application thereof | 中国药科大学 | 2021-06-11 | — | — | CN | claimed |
| CN-112057434-A | Mesoporous silicon nano particle capable of responding X-ray medicine release and preparation method and application thereof | 华南理工大学 | 2020-12-11 | — | — | CN | claimed |
| US-10584317-B2 | Modified vaccinia virus strains for use in diagnostic and therapeutic methods | GENELUX CORPORATION (US) | 2020-03-10 | — | — | US | claimed |
| CN-110354099-A | A kind of Nano medication system and its preparation method and application with the double transfer characteristics of hydrophobe-size based on proton triggering | 中国药科大学 | 2019-10-22 | — | — | CN | claimed |
| CN-109806252-A | Tri compound nanometer system and its preparation method and application | 中国药科大学 | 2019-05-28 | — | — | CN | claimed |
| CN-106279635-B | Class antibacterial peptide and vesica and its preparation method and application | 同济大学 | 2019-01-25 | — | — | CN | claimed |
| CN-109045347-A | A kind of degradable load medicine hemostatic microsphere and preparation method thereof | 温州生物材料与工程研究所 | 2018-12-21 | — | — | CN | claimed |
| EP-1911449-A1 | ANTI-TUMOR AGENT COMPRISING 6'-AMIDINO-2'-NAPHTHYL4- GUANIDINOBENZOATE OR SALT THEREOF | TORII PHARMACEUTICAL CO., LTD. (JP) | 2008-04-16 | — | — | EP | claimed |
| CN-101098684-A | Composition for preventing and treating radical diseases | VITAMIN C60 BIORES CORP (JP) | 2008-01-02 | — | — | CN | claimed |
| EP-1834637-A1 | PREVENTIVE/THERAPEUTIC COMPOSITION FOR FREE RADICAL DISEASE | Vitamin C60 Bioresearch Corporation (JP) | 2007-09-19 | — | — | EP | claimed |
| US-20020010210-A1 | PHARMACEUTICAL PREPARATION AND METHOD FOR TREATING CANCER | SHOWA DENKO KABUSHIKI KAISHA (JP) | 2002-01-24 | — | — | US | claimed |
| EP-0875246-A1 | Pharmaceutical preparation of ascorbic acid derivatives for medical treatment of cancer | SHOWA DENKO KABUSHIKI KAISHA (JP) | 1998-11-04 | — | — | EP | claimed |
| EP-0608546-A2 | Glia activating factor (GAF), antibodies against it and their uses | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1994-08-03 | — | — | EP | claimed |
| EP-0132105-B1 | OILY COMPOSITION OF ACLARUBICIN OR HYDROCHLORIDE THEREOF | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 1990-10-31 | — | — | EP | claimed |
| US-4772590-A | Oily composition of aclarubicin or hydrochloride thereof | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 1988-09-20 | — | — | US | claimed |
| US-4578391-A | Oily compositions of antitumor drugs | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 1986-03-25 | — | — | US | claimed |
| EP-0132105-A2 | Oily composition of aclarubicin or hydrochloride thereof | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 1985-01-23 | — | — | EP | claimed |